Articles tagged with Parkinsons Disease
A study by Massachusetts General Hospital researchers found that mice with elevated urate levels showed significantly less neurodegeneration and improved movement abnormalities compared to those with low urate levels. The results support the possibility that increasing urate levels may slow progression of Parkinson's disease.
Researchers at AxoGlia Therapeutics and the Luxembourg Centre for Systems Biomedicine have received a grant to identify new neuroprotective therapeutic targets for Parkinson's disease. The project aims to disrupt the CD40/CD40-Ligand neuroinflammatory pathway, which could lead to new avenues for therapeutic interventions.
Researchers at Rensselaer Polytechnic Institute have created novel antibodies that can prevent the formation of toxic protein particles linked to diseases such as Alzheimer's and Parkinson's. These antibodies bind to 10 proteins per molecule, making them more potent inhibitors than conventional antibodies.
Researchers developed a way to derive dopaminergic neurons from adult bone marrow stem cells in monkeys. The new neurons were then transplanted into the same monkeys with induced Parkinson's disease, showing significant improvement in motor function.
Researchers found that GM1 ganglioside improved symptoms and slowed disease progression in patients with Parkinson's disease over a 2.5-year period. The study enrolled 77 subjects and followed them for 120 weeks, with significant benefits observed when participants stopped taking the drug.
A new MRI technique has provided the first clinical evidence for the theory that Parkinson's neurodegeneration begins deep in the brain and advances upward. The study found significant loss of volume in the substantia nigra early on, followed by loss of basal forebrain volume later in the disease.
A study found that exercise programs on stationary bicycles improve Parkinson's disease symptoms, with faster pedaling leading to greater brain connectivity and motor ability improvements. The therapy is low-cost and effective, even for patients who don't need forced-rate exercise.
A new diagnostic method for Parkinson's disease is noninvasive and effective in over 90% of cases. The method tracks speech patterns to detect the disorder's early signs.
Researchers discovered that yeast protein Hsp104 can break up both amyloid fibrils and disordered protein clumps, with different requirements for stability. This finding offers a new approach to eliminate toxic clumps linked with neurodegenerative diseases.
A Scripps Research Institute team has identified a key factor controlling damage to brain cells in a mouse model of Parkinson's disease. The discovery, led by scientist Bruno Conti, points to the IL-13 receptor as a potential target for new treatment options.
Researchers at the University of Pennsylvania School of Medicine have found that injecting synthetic, misfolded α-Syn protein into healthy mice recapitulates Parkinson's disease progression, leading to dopamine neuron death and Lewy body formation. The study establishes a mechanistic link between α-Syn transmission and neurodegeneration.
A new study published by the American Academy of Neurology reveals a significant link between head injuries and pesticide exposure to an increased risk of Parkinson's disease. People with Parkinson's were found to be three times more likely to have had a head injury and exposure to paraquat, a common herbicide.
The University of Granada and the Michael J. Fox Foundation have developed advanced imaging techniques to diagnose Parkinson's disease, improving accuracy and reducing reliance on expert analysis. The new methods utilize machine learning algorithms to analyze brain function and image data, demonstrating promising results in diagnosis.
Researchers have created a new family of compounds that could slow Parkinson's disease progression by shutting down the Cav1.3 channel, which allows calcium to flood into dopamine neurons. The compounds were developed by Northwestern University scientists and show promise in animal trials without obvious side effects.
The Antarctic Ocean has seen a steady increase in sea ice cover over the past three decades, growing by approximately 6,600 square miles annually. This growth is attributed to changes in atmospheric circulation and a depleted ozone layer over Antarctica, which leads to cooling of the stratosphere and strengthening of circumpolar winds.
Salk scientists pinpointed damage to neural stem cells, specifically deformed nuclear envelopes, leading to neuronal loss and dysfunction in Parkinson's patients. The discovery may lead to new diagnostic and therapeutic approaches, including targeted gene-editing technologies.
Researchers at the University of Pennsylvania found a significant association between myasthenia gravis and impaired sense of smell, comparable to Alzheimer's disease and Parkinson's. The study suggests that myasthenia gravis may involve the brain, contrary to its traditional peripheral nervous system classification.
Extradural brain stimulation has been shown to be safe and effective in improving movement disorder symptoms for patients with Parkinson's disease. The technique, called EMCS, provides a less-invasive alternative to electrical deep brain stimulation (DBS) and led to small but significant improvements in voluntary movement control.
Researchers found that rapamycin can extract a balance between UCHL1 and its mirror protein, holding them together in the cytoplasm to correct mistakes in Parkinson's disease. The drug may delay onset of diseases like Alzheimer's and Parkinson's by correcting protein imbalance.
Common sporadic Parkinson's disease arises from excess alpha-synuclein protein in dopamine neurons, which can be treated with drugs targeting elongated transcript forms. A blood test for alpha-synuclein may serve as a biomarker for the disease.
Researchers found that auditory cues had the greatest influence on human gait, while visual cues had no significant effect. The study suggests that auditory cues could be particularly helpful for patients with Parkinson's Disease in their rehabilitation.
New research reveals professional football players are three times more likely to die from brain-damaging diseases compared to the general population. The study found a significant increase in deaths from Alzheimer's disease and ALS among speed position players, highlighting potential risks of chronic traumatic encephalopathy (CTE).
Scientists at UH Center for Nuclear Receptors and Cell Signaling discovered LXRbeta, a nuclear receptor that promotes the survival of dopaminergic neurons, which are the main source of dopamine in the central nervous system. The presence of LXRbeta may offer protection against neurodegeneration of the midbrain.
People with Parkinson's disease performed better on a working memory test after a night's sleep, with slow wave sleep linked to improved performance. Sleep disorders can interfere with this benefit, and dopamine-enhancing medications may play a role in memory improvement.
A study found that caffeine supplements improved Parkinson's severity ratings and speed of movement by 3 points, but did not affect daytime sleepiness or quality of life. The results suggest that caffeine may be a useful treatment option for some patients with Parkinson's disease.
A study at McGill University Health Centre found that caffeine improved motor symptoms in people with Parkinson's disease by increasing speed of movement and reducing stiffness. Larger-scale studies are needed to confirm these findings and explore caffeine as a treatment option.
Researchers have discovered a powerful class of antioxidants that can block the development of Parkinson's disease by bolstering the natural antioxidant Nrf2. The synthetic triterpenoids increased Nrf2 activity, reducing oxidative stress and inflammation in brain cells, which are characteristic of Parkinson's.
Researchers found that severe influenza infection doubles the odds of developing Parkinson's disease later in life, whereas a typical case of red measles as a child reduces the risk by 35%. The study also suggests an association between high-intensity vibrations and increased Parkinson's risk.
Researchers derived iPS cells from patients with genetic forms of Parkinson's and found common signs of distress in neurons, including abnormalities in mitochondria. The cells' responses to treatments depended on the type of Parkinson's each patient had.
Embryonic stem cells can be used to replace dopamine-producing cells in Parkinson's disease patients with high efficiency. Researchers have identified specific genes associated with each stage of neuronal differentiation, allowing for more precise cell purification strategies.
Researchers at BUSM found increased expression of FOXO1 gene in Parkinson's disease brain tissue samples. Two single-nucleotide polymorphisms associated with age at onset were also discovered, providing new insights into the genetic mechanisms of Parkinson's.
A Canadian Mennonite family of Dutch-German-Russian ancestry has contributed to the identification of the DNAJC13 gene associated with late-onset Lewy body Parkinson's disease, according to UBC researchers. The study provides new insights into the genetic aspects of PD and offers hope for effective treatments and a cure.
Researchers have identified a process by which misfolded proteins, such as alpha-synuclein, travel from sick to healthy cells in the brain, leading to the progression of Parkinson's disease. The study provides new insights into the disease's pathology and offers potential targets for disease-modifying treatments.
A study found that deep brain stimulation (DBS) treatment effectively improved motor function in Parkinson's disease patients for at least three years. However, improvements in health-related quality of life and cognitive abilities were gradually lost over time., The treatment was most effective for reducing tremors and muscle rigidity.
Researchers found that urate protects cultured brain cells against Parkinson-like damage by involving astrocytes. The study suggests multiple ways to raise urate levels to protect against neurodegeneration in diseases like Parkinson's.
Researchers found two specific gene variants associated with faster motor decline in Parkinson's patients. These variants can now help doctors predict disease progression, allowing for targeted therapies and faster results on efficacy of drugs.
Researchers at Rush University Medical Center have discovered alpha-synuclein protein in the intestinal wall of patients with early Parkinson's disease, but not healthy subjects. This finding may lead to pre-motor diagnosis and accurate biomarkers for tracking its progress.
Researchers found that vitamin K2 can restore energy production in defective mitochondria, similar to those found in Parkinson's patients. This discovery offers potential treatment options for patients with the disease.
Dr. Samuel Young receives grant to develop critical technology for researching potential therapies targeting LRRK2, a key Parkinson's-related gene. The technology aims to overcome challenges in expressing the gene using commonly used neuroscience research tools.
Researchers at Tel Aviv University develop a peptide therapy that mimics DJ-1's normal function, protecting dopamine-producing neurons and reducing mobility dysfunctions. The treatment has shown promising results in pre-clinical trials on mice, indicating a viable option for Parkinson's patients.
Dr. Timothy J. Collier received the 2012 Bernard Sanberg Memorial Award for Brain Repair for his work on cellular repair for Parkinson's disease, while Dr. Sean I. Savitz was honored with the Molly and Bernard Sanberg Memorial Award for his contributions to cell-based therapies for ischemic stroke.
Researchers at Gladstone Institutes have discovered a specific brain circuitry associated with addictive and depressive behaviors. The study found that an imbalance in medium spiny neurons controlling movement also contributes to psychiatric disorders.
Researchers found that alpha-synuclein protein aggregates in ring structures within neuron membranes, causing cell damage and symptoms of Parkinson's disease. The study provides a step-by-step explanation of how these aggregates form and offers hope for developing drugs to slow disease progression.
Researchers found that alpha-synuclein fibrils can induce normal a-syn to misfold, leading to neurodegeneration. The study suggests that the corrupted form of a-syn can be transmitted from diseased neurons to healthy ones via white-matter tracks.
A phase three clinical trial shows LCIG reduces 'off' time by an average of nearly two extra hours per day compared to standard levodopa-carbidopa therapy. This innovation delivers levodopa-carbidopa continuously, minimizing fluctuations that contribute to wearing off.
A team studied mice with a mutated form of alpha-synuclein, finding that injected clumps accelerated disease onset and severity. The clumps seemed to hijack brain signals, spreading throughout the brain.
A new study published in Neurology found that antidepressant medications can effectively treat depression in Parkinson's patients without worsening their motor symptoms. The study, led by Irene Hegeman Richard, M.D., showed significant improvements in depression scores with paroxetine and venlafaxine, two commonly used antidepressants.
A study published in Neurology found that certain antidepressants decrease depression in people with Parkinson's disease without worsening motor problems. The study used paroxetine and venlafaxine, two types of antidepressants with fewer side effects, and showed significant improvements in depression scores.
A study of 112 patients with Parkinson's disease and 60 controls found that persistent ocular tremors were universally present in patients with PD, regardless of medication use. This finding suggests that precise oculomotor testing could be a valuable tool for early diagnosis.
A new study published in Neurology finds that consuming flavonoids, particularly anthocyanins found in berries, can significantly reduce the risk of developing Parkinson's disease. Male participants who ate the most flavonoids were 40% less likely to develop the disease than those who ate the least.
A PET imaging agent has been shown to reverse neurotoxicity and improve motor skills and memory in animal models of Parkinson's disease. The compound works as a scavenger of peroxynitrite, reducing neuronal death and promoting revival of neuronal function.
A Mayo Clinic study found that people with rapid eye movement sleep behavior disorder are twice as likely to develop mild cognitive impairment or Parkinson's disease within four years. Researchers used the Mayo Sleep Questionnaire to diagnose probable RBD in neurologically normal individuals.
A study published in Archives of Neurology found a possible association between statin use and reduced risk of developing Parkinson's disease, particularly among younger individuals. The research included over 38,000 men and women and followed them for 12 years, documenting 644 incident PD cases.
Scientists from Scripps Research Institute have discovered a compound, SR 3306, that blocks the destruction of brain cells in animal models of Parkinson's disease. The new compound could potentially be the first to protect the brain from the ravages of the disease.
Researchers at UCLA have discovered a novel compound called CLR01 that prevents α-synuclein protein aggregates from forming, stopping their toxicity and even breaking up existing aggregates in the brain. This breakthrough holds promise for slowing or stopping Parkinson's disease progression and may lead to human clinical trials.
Researchers found that Parkinson's disease patients who took dopamine therapy showed improved creative skills, including drawing, painting, poetry, and sculpture. However, the study also revealed a lack of correlation between creative thinking scores and impulsivity measures.
Researchers at Purdue University have discovered a protein mutation that disrupts the protective function of DJ-1, a key player in preventing neuronal death in Parkinson's disease. This finding may lead to new treatment strategies by targeting this error in the protein.
A two-year clinical trial showed that weight training significantly improved motor symptoms of Parkinson's disease compared to stretching and balance exercises. Weight training led to a 7.3 point improvement in UPRDS scores after two years, while fitness counts group returned to baseline scores.
A study published in the New England Journal of Medicine found that a tailored Tai Chi training program significantly improved postural stability and walking ability in Parkinson's disease patients. The program resulted in reduced falls and demonstrated potential as an add-on to current physical therapies.
University of Alabama researchers have identified the neuro-protective capability of the VPS41 gene in both animal models and human neurons, providing a potential step toward developing a new drug treatment for Parkinson's disease. The study found that specific changes in human DNA may impact how VPS41 functions.